Obstetric maneuvers for shoulder dystocia.

L. Iffy,V. Ganesh,L. Gittens

DOI: https://doi.org/10.1016/S0002-9378(98)60166-6

IF: 9.8

1998-11-01

American Journal of Obstetrics and Gynecology

Abstract:

What problem does this paper attempt to address?

Psychedelic research at a crossroads

Stacey B. Armstrong,Alan K. Davis

DOI: https://doi.org/10.1126/science.adt1024

IF: 56.9

2024-09-21

Science

Abstract:There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have been combined with psychotherapy and studied in clinical trials in the United States and Europe. Psychedelics are hallucinogenic drugs that alter brain activity and facilitate altered states of consciousness. The proposed benefits of psychedelic-assisted therapy (PAT) include relatively short treatment times and stronger effects compared to other treatments. Although results of trials using MDMA for trauma or psilocybin for depression are promising, PAT is controversial because many questions about its safety and effectiveness are unanswered. This is evident in the recent ruling by the US Food and Drug Administration against the approval of MDMA therapy for post-traumatic stress disorder and the retraction of several papers about MDMA trials owing to unethical conduct by study therapists and data integrity, among other concerns. This field is at a crossroads, and the research community must address several obstacles to transition from exploratory trials to established, evidence-based treatments while avoiding pitfalls that can hinder advancement.

multidisciplinary sciences
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Sean J Belouin,Lynnette A Averill,Jack E Henningfield,Stephen N Xenakis,Ingrid Donato,Charles S Grob,Ann Berger,Veronica Magar,Alicia L Danforth,Brian T Anderson

DOI: https://doi.org/10.1016/j.neuropharm.2022.109214

IF: 5.273

2022-11-15

Neuropharmacology

Abstract:There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food and Drug Administration and may potentially receive full FDA approval with similar regulatory considerations occurring in multiple countries. At the same time, regulatory changes are poised to increase access to legal or decriminalized psychedelic use in various non-medical settings. This review provides a brief discussion on the historical use of psychedelic medicines, the status of the empirical evidence, and numerous significant policy considerations that must be thoughtfully addressed regarding standards-of-practice, consumer protection, engagement of communities, safeguarding access for all, and developing data standards, which supports the responsible, accountable, safe, and ethical uses of these medicines in clinical, faith-based, and other contexts. We provide suggestions for how public health and harm reduction can be supported through a public-private partnership that engages a community of stakeholders from various disciplines in the co-creation and dissemination of best practices and public policies.
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

Tamara Valdez,Valbhi Patel,Nattaphone Senesombath,Zayd Hatahet-Donovan,Mary Hornick

DOI: https://doi.org/10.3390/ph17111484

IF: 4.6

2024-11-06

Pharmaceuticals

Abstract:Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have historically hindered further research into this area. Nevertheless, concurrent with the rise in SUDs and other mental health conditions, researchers have again turned their attention to these compounds, searching for differing pharmacological targets as well as more holistic treatments that might increase patient adherence and efficacy. The aim of this review is to examine the emerging evidence-based data with regards to the therapeutic treatment of SUDs with the psychedelic compounds psilocybin, ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ayahuasca, ibogaine and peyote.

pharmacology & pharmacy,chemistry, medicinal
The cyclical revival of psychedelics in psychiatric treatment

Francisco J. Appiani,Stanley N. Caroff

DOI: https://doi.org/10.1080/03007995.2024.2368725

2024-06-22

Current Medical Research and Opinion

Abstract:There is an increasing demand for effective treatments for depression, particularly for individuals grappling with treatment-resistant depression. Over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. However, preliminary findings from phase 2 studies have been inconclusive, prompting critical examination of issues such as maintaining blinding and the role of adjunctive psychotherapy. The maintenance of double-blinding and the role of adjunctive psychotherapy introduce biases that complicate the attainment of conclusive results in clinical research. Examining historical data reveals a recurrent pattern linked to the use of psychoactive substances, which starts with an excess of optimism and ends with general addictive behaviors and a heightened risk of serious public health problems. Considering these findings, a cautious and measured approach is imperative, given that the efficacy and safety of psilocybin treatment have yet to be unequivocally established. The potential for excessive optimism among researchers is a notable concern, as unwarranted enthusiasm may inadvertently facilitate the widespread adoption of this treatment without sufficient empirical support. In navigating the complexities of depression treatment, it is necessary to strike a balance between innovation and prudence to ensure evidence-based advancement of therapeutic approaches.

medicine, general & internal, research & experimental
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

Ioanna A Vamvakopoulou,David J Nutt

DOI: https://doi.org/10.1159/000540062

Abstract:Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid diethylamide [LSD], dimethyltryptamine [DMT], mescaline) and atypical (ketamine, ibogaine, 5-MeO-DMT, 3,4-methylenedioxymethamphetamine) psychedelics for the treatment of addiction. Summary: We will start with an overview of the pharmacology and physiological and psychological properties of psychedelic substances from pre-clinical and clinical research. We will then provide an overview of evidence gathered by studies conducted in controlled research environments and naturalistic and ceremonial settings, while we identify the proposed therapeutic mechanisms of each psychedelic substance. Key messages: Classic and atypical psychedelics show promise as therapeutic alternatives for the treatment of addiction, through the improvement of psychological and physiological symptoms of dependence. A more comprehensive understanding of the ancient and present-day knowledge of the therapeutic potential of psychedelics can facilitate hope for psychedelic therapeutics in the treatment of addiction, especially for individuals who have failed other conventional treatment methods.
Psychedelics and Other Psychoplastogens for Treating Mental Illness

Maxemiliano V. Vargas,Retsina Meyer,Arabo A. Avanes,Mark Rus,David E. Olson

DOI: https://doi.org/10.3389/fpsyt.2021.727117

IF: 4.7

2021-10-04

Frontiers in Psychiatry

Abstract:Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others. Psychedelics belong to a more general class of compounds known as psychoplastogens, which robustly promote structural and functional neural plasticity in key circuits relevant to brain health. Here we discuss the importance of structural plasticity in the treatment of neuropsychiatric diseases, as well as the evidence demonstrating that psychedelics are among the most effective chemical modulators of neural plasticity studied to date. Furthermore, we provide a theoretical framework with the potential to explain why psychedelic compounds produce long-lasting therapeutic effects across a wide range of brain disorders. Despite their promise as broadly efficacious neurotherapeutics, there are several issues associated with psychedelic-based medicines that drastically limit their clinical scalability. We discuss these challenges and how they might be overcome through the development of non-hallucinogenic psychoplastogens. The clinical use of psychedelics and other psychoplastogenic compounds marks a paradigm shift in neuropsychiatry toward therapeutic approaches relying on the selective modulation of neural circuits with small molecule drugs. Psychoplastogen research brings us one step closer to actually curing mental illness by rectifying the underlying pathophysiology of disorders like depression, moving beyond simply treating disease symptoms. However, determining how to most effectively deploy psychoplastogenic medicines at scale will be an important consideration as the field moves forward.

psychiatry
Psychedelics and Neural Plasticity: Therapeutic Implications

Grieco,S. F.,Castren,E.,Knudsen,G. M.,Kwan,A. C.,Olson,D. E.,Zuo,Y.,Holmes,T. C.,Xu,X.

DOI: https://doi.org/10.1523/JNEUROSCI.1121-22.2022

2022-11-10

Journal of Neuroscience

Abstract:Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural attitudes toward them are changing, and scientists are once again investigating the neural mechanisms through which these drugs impact brain function. The significance of this research direction is reflected by recent work, including work presented by these authors at the 2022 meeting of the Society for Neuroscience. As of 2022, there were hundreds of clinical trials recruiting participants for testing the therapeutic effects of psychedelics. Emerging evidence suggests that psychedelic drugs may exert some of their long-lasting therapeutic effects by inducing structural and functional neural plasticity. Herein, basic and clinical research attempting to elucidate the mechanisms of these compounds is showcased. Topics covered include psychedelic receptor binding sites, effects of psychedelics on gene expression, and on dendrites, and psychedelic effects on microcircuitry and brain-wide circuits. We describe unmet clinical needs and the current state of translation to the clinic for psychedelics, as well as other unanswered basic neuroscience questions addressable with future studies.

neurosciences
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Franz X. Vollenweider,Katrin H. Preller

DOI: https://doi.org/10.1038/s41583-020-0367-2

IF: 38.755

2020-09-14

Nature Reviews Neuroscience

Abstract:Renewed interest in the use of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. After a hiatus of about 50 years, state-of-the art studies have recently begun to close important knowledge gaps by elucidating the mechanisms of action of psychedelics with regard to their effects on receptor subsystems, systems-level brain activity and connectivity, and cognitive and emotional processing. In addition, functional studies have shown that changes in self-experience, emotional processing and social cognition may contribute to the potential therapeutic effects of psychedelics. These discoveries provide a scientific road map for the investigation and application of psychedelic substances in psychiatry.

neurosciences
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Oliver Rumle Hovmand,Emil Deleuran Poulsen,Sidse Arnfred,Ole Jakob Storebø

DOI: https://doi.org/10.1177/02698811231180276

2023-07-06

Journal of Psychopharmacology

Abstract:Journal of Psychopharmacology, Ahead of Print. Background:The classical psychedelics, psilocybin, peyote, ayahuasca/N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promising new treatments for psychiatric illnesses, such as depression, anxiety, addiction, and obsessive-compulsive disorders. However, their profound and characteristic subjective effects raise concern for distinctive biases in randomized clinical trials.Methods:We performed a systematic literature search to identify all clinical trials on classical psychedelics with patient populations to examine descriptive data and determine the risk of bias. Two independent reviewers searched three databases (PubMed, Embase, and APA PsycNet) and extracted information on study design, study population, use of active or inactive placebo, dropouts, evaluation of blinding of intervention, and reporting of expectancy and therapeutic alliance.Results:We included 10 papers reporting on 10 unique trials. The trials generally included populations that were predominantly white and highly educated. The trials had small samples and considerable dropout. Blinding was either unsuccessful or not reported regardless of type of placebo. Few trials published protocols, statistical analysis plans (SAPs), and outcomes relating to psychotherapy fidelity. All trials but one were rated as high risk of bias.Conclusion:Successful blinding of intervention is a significant challenge in this field. To better accommodate this, we suggest that future trials use a parallel-group design and utilize an active placebo on a psychedelic-naïve population. Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.

pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
Fragile promise of psychedelics in psychiatry

Cédric Lemarchand,Raphaël Chopin,Morgane Paul,Alain Braillon,Lisa Cosgrove,Ioana Cristea,Eiko I Fried,Erick H Turner,Florian Naudet

DOI: https://doi.org/10.1136/bmj-2024-080391

2024-11-27

BMJ

Abstract:The US clinical market for ketamine, estimated at $3.1bn in 2022 and expected to expand at 10.6% a year until 2030,1 is just one of many signs of renewed interest in the use of psychedelics to treat psychiatric conditions.2 Various mind altering drugs have already entered the market, including esketamine nasal spray, which the US Food and Drug Administration approved in 2019. And in 2022 the Australian Therapeutic Goods Administration (TGA) allowed psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) to be prescribed by authorised physicians for psychiatric conditions such as depression and post-traumatic stress disorder. The decision was taken despite an independent scientific report commissioned by the TGA advising against authorisation because the certainty of evidence for benefits was low or very low.3Psychedelics, the lay term for substances classified as hallucinogens, have various targets and distinct purported mechanisms of action. For instance, psilocybin is a serotoninergic agonist, whereas esketamine is a N-methyl-D-aspartate (NMDA)...

medicine, general & internal
Preliminary Studies of Fructan‐Hydrolyzing Bacteria from Human Dental Plaque

K. Takamori,F. Mizuno,A. Yamamoto,Y. Etoh,Mitsuyoshi Takahashi,N. Takahashi

DOI: https://doi.org/10.1111/j.1348-0421.1985.tb00834.x

1985-04-01

Microbiology and Immunology

Abstract:Fructans in dental plaque contain two different types of fructopolysaccharides : one is the levan-type with (2,6)-linked ƒA-fructofuranoside residues and the other is the inulin-type with (2,1)-linked jS-fructofuranoside residues (4). Fructans formed in plaque serve as an exogenous carbohydrate source for plaque bacteria (11), and become gradually hydrolyzed by such bacteria, resulting in continued acid
Psychedelic therapy in depression and substance use disorders

Nur Damla Korkmaz,Ugur Cikrikcili,Merve Akan,Emrah Yucesan

DOI: https://doi.org/10.1111/ejn.16421

IF: 3.698

2024-05-23

European Journal of Neuroscience

Abstract:Psychedelics changes in perception through serotonin receptor agonism. Effects on the 5HT2A receptor; neuroplasticity and transcriptomic regulation, as well as specific changes in neural correlates of brain networks. Psychedelic‐assisted therapy in disorders such as depression, anxiety and substance use disorders constitutes a strong research area, thus evaluating the clinical use is highly essential (this figure was created with BioRender.com). Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5‐HT2A receptor activation. Lysergic acid diethylamide, the first famous breakthrough in the field, was discovered by chance by Albert Hoffman in the Zurich Sandoz laboratory in 1943, and studies on its psychoactive effects began to take place in the literature. Studies in this area were blocked after the legislation controlling the use and research of psychedelic drugs came into force in 1967, but since the 1990s, it has started to be a matter of scientific curiosity again by various research groups. In particular, with the crucial reports of psychotherapy‐assisted psilocybin applications for life‐threatening cancer‐related anxiety and depression, a new avenues have been opened in the treatment of psychiatric diseases such as treatment‐resistant depression and substance addictions. An increasing number of studies show that psychedelics have a very promising potential in the treatment of neuropsychiatric diseases where the desired efficiency cannot be achieved with conventional treatment methods. In this context, we discuss psychedelic therapy, encompassing its historical development, therapeutic applications and potential treatment effects—especially in depression, trauma disorders and substance use disorders—within the framework of ethical considerations.

neurosciences
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Danilo De Gregorio,Argel Aguilar-Valles,Katrin H Preller,Boris Dov Heifets,Meghan Hibicke,Jennifer Mitchell,Gabriella Gobbi,Katrin H. Preller

DOI: https://doi.org/10.1523/JNEUROSCI.1659-20.2020

2021-02-04

Journal of Neuroscience

Abstract:A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of psilocybin and LSD, as well as their ability to modulate functional brain connectivity. Moreover, MDMA, a compound belonging to the family of entactogens, has been demonstrated to be useful to treat post-traumatic stress disorders. In this review, the pharmacology of hallucinogenic compounds is summarized by underscoring the differences between psychedelic and nonpsychedelic hallucinogens as well as entactogens, and their behavioral effects in both animals and humans are described. Together, these data substantiate the potentials of these compounds in treating mental diseases.

neurosciences
Reviewing the Potential of Psychedelics for the Treatment of PTSD

Erwin Krediet,Tijmen Bostoen,Joost Breeksema,Annette van Schagen,Torsten Passie,Eric Vermetten

DOI: https://doi.org/10.1093/ijnp/pyaa018

2020-03-14

Abstract:Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.

pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Claudio Agnorelli,Meg Spriggs,Kate Godfrey,Gabriela Sawicka,Bettina Bohl,Hannah Douglass,Andrea Fagiolini,Hashemi Parastoo,Robin Carhart-Harris,David Nutt,David Erritzoe

2024-11-30

Abstract:Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment target for neuropsychiatric conditions. Psychedelics, a burgeoning category of drugs, are increasingly prominent in psychiatric research, prompting inquiries into their mechanisms of action. Distinguishing themselves from traditional medications, psychedelics demonstrate rapid and enduring therapeutic effects after a single or few administrations, believed to stem from their neuroplasticity-enhancing properties. This review examines how classic psychedelics (e.g., LSD, psilocybin, N,N-DMT) and non-classic psychedelics (e.g., ketamine, MDMA) influence neuroplasticity. Drawing from preclinical and clinical studies, we explore the molecular, structural, and functional changes triggered by these agents. Animal studies suggest psychedelics induce heightened sensitivity of the nervous system to environmental stimuli (meta-plasticity), re-opening developmental windows for long-term structural changes (hyper-plasticity), with implications for mood and behavior. Translating these findings to humans faces challenges due to limitations in current imaging techniques. Nonetheless, promising new directions for human research are emerging, including the employment of novel positron-emission tomography (PET) radioligands, non-invasive brain stimulation methods, and multimodal approaches. By elucidating the interplay between psychedelics and neuroplasticity, this review informs the development of targeted interventions for neuropsychiatric disorders and advances understanding of psychedelics' therapeutic potential.

Neurons and Cognition,Biomolecules
Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

Logan Neitzke-Spruill,Nese Devenot,Dominic Sisti,Lynnette A. Averill,Amy L. McGuire

DOI: https://doi.org/10.1353/pbm.2024.a919715

2024-01-01

Perspectives in Biology and Medicine

Abstract:ABSTRACT: Psychedelics have again become a subject of widespread interest, owing to the reinvigoration of research into their traditional uses, possible medical applications, and social implications. As evidence for psychedelics' clinical potential mounts, the field has increasingly focused on searching for mechanisms to explain the effects of psychedelics and therapeutic efficacy of psychedelic-assisted therapy (PAT). This paper reviews three general frameworks that encompass several prominent models for understanding psychedelics' effects—specifically, neurobiological, psychological, and spiritual frameworks. Following our review, the implications of each framework for ethics and professional competencies in the implementation of psychedelics as medicines are explored. We suggest that interdisciplinary education may be necessary to improve communication between researchers, develop models that effectively incorporate multiple levels of analysis, and facilitate collaboration between professionals with diverse backgrounds in the implementation of psychedelic medicines. We also address pitfalls associated with overemphasis on neuro-mechanisms, risks associated with instigating vulnerable states of consciousness, and hurdles associated with the integration of spiritual frameworks in medicine. Ultimately, as psychedelics push the boundaries of explanatory frameworks focused on one level of analysis, developing new and more useful models to reflect knowledge being produced in this field should be a central aim of psychedelic science going forward.

medicine, research & experimental,history & philosophy of science
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Tamar Glatman Zaretsky,Kathleen M. Jagodnik,Robert Barsic,Josimar Hernandez Antonio,Philip A. Bonanno,Carolyn MacLeod,Charlotte Pierce,Hunter Carney,Morgan T. Morrison,Charles Saylor,George Danias,Lauren Lepow,Rachel Yehuda

DOI: https://doi.org/10.2174/1570159x22666231027111147

2024-04-01

Current Neuropharmacology

Abstract:Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant proportion of patients receiving standard-of-care therapies for PTSD remain symptomatic, and new approaches for this and other trauma-related mental health conditions are greatly needed. Psychedelic compounds that alter cognition, perception, and mood are currently being examined for their efficacy in treating PTSD despite their current status as Drug Enforcement Administration (DEA)- scheduled substances. Initial clinical trials have demonstrated the potential value of psychedelicassisted therapy to treat PTSD and other psychiatric disorders. In this comprehensive review, we summarize the state of the science of PTSD clinical care, including current treatments and their shortcomings. We review clinical studies of psychedelic interventions to treat PTSD, trauma-related disorders, and common comorbidities. The classic psychedelics psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) and DMT-containing ayahuasca, as well as the entactogen 3,4-methylenedioxymethamphetamine (MDMA) and the dissociative anesthetic ketamine, are reviewed. For each drug, we present the history of use, psychological and somatic effects, pharmacology, and safety profile. The rationale and proposed mechanisms for use in treating PTSD and traumarelated disorders are discussed. This review concludes with an in-depth consideration of future directions for the psychiatric applications of psychedelics to maximize therapeutic benefit and minimize risk in individuals and communities impacted by trauma-related conditions.

pharmacology & pharmacy,neurosciences
Morphological cues to verb meaning: verb inflections and the initial mapping of verb meanings

D. Behrend,L. Lynn Harris,Kelly B. Cartwright

DOI: https://doi.org/10.1017/S0305000900009648

IF: 2.7007

1995-02-01

Journal of Child Language

Abstract:ABSTRACT The present studies investigated children's use of verb inflections to guide their initial mapping of verb meanings. Given that children initially apply the progressive -ing inflection to verbs denoting actions and the past -ed inflection to verbs denoting results of events, two studies were conducted to investigate whether children use these inflections during mapping of novel verb meanings. In both studies, subjects were taught novel verbs and were asked to extend those verbs to events in which the action or result differed from events used to teach the verbs. It was predicted that subjects would be less likely to extend verbs inflected with -ing to events with new actions and would be less likely to extend verbs inflected with -ed to events with new results. Eighteeen three- and five-year-olds and 24 adults participated in Experiment 1 in a between-subjects design that produced weak effects for the youngest subjects tested. Experiment 2 tested 16 three-year-olds and 19 five-year-olds in a within-subjects design and produced the predicted effect for three-year-olds, but not for five-year-olds. The findings are discussed in terms of their implications for early verb learning and regarding the use of the bootstrapping construct in language acquisition research.
Exploring the regulatory framework of psychedelics in the US & Europe

Hitesh Kumar Behera,Ramesh Joga,Sravani Yerram,Praveena Karnati,Tejaswini Mergu,Kajal Gandhi,Sowndharya M,Deepak Nathiya,Ravindra Pal Singh,Saurabh Srivastava,Sandeep Kumar

DOI: https://doi.org/10.1016/j.ajp.2024.104242

2024-09-17

Abstract:Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory approvals of key psychedelic substances like psilocybin, 3,4-Methyl enedioxy methamphetamine (MDMA), mescaline, ketamine, and Lysergic acid diethylamide (LSD). It also provides an overview of legal aspects, and regulations surrounding psychedelics in the US & Europe, emphasizing their Schedule I classification due to potential misuse. The United States Food & Drug Administration (USFDA) closely monitors psychedelics, employing expedited pathways for evaluation. Further, recent guidance from the FDA on considerations for clinical Investigations supports the safe development of psychedelics for human welfare. European Medicines Agency (EMA) regulators focus on atypical psychedelics, addressing challenges in safety and efficacy. Marketed products, such as Spravato nasal spray, face limited distribution due to safety concerns. The call for careful regulation and legislation is essential for harnessing psychedelics' potential for therapeutic benefits and human welfare.
Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Owen S. Muir,Kenneth Shinozuka,Bryce D. Beutler,Alejandro Arenas,Kirsten Cherian,Viviana D. Evans,Chelsey Fasano,Burton J. Tabaac

DOI: https://doi.org/10.1097/mjt.0000000000001720

2024-03-23

American Journal of Therapeutics

Abstract:The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically, psychiatric pathologies have been treated with small-molecule compounds that have limited effect sizes and carry a variety of adverse effect profiles. Psychedelic medicines offer the opportunity to provide more potent and rapidly acting treatments. It is crucial to note that this is an emerging field of medicine, and only one of these compounds (esketamine) is currently Food and Drug Administration-approved for depression. The other compounds discussed are investigational, and this discussion is both imaginative and prospective in nature.

pharmacology & pharmacy

Obstetric maneuvers for shoulder dystocia.

Psychedelic research at a crossroads

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

The cyclical revival of psychedelics in psychiatric treatment

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

Psychedelics and Other Psychoplastogens for Treating Mental Illness

Psychedelics and Neural Plasticity: Therapeutic Implications

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Fragile promise of psychedelics in psychiatry

Preliminary Studies of Fructan‐Hydrolyzing Bacteria from Human Dental Plaque

Psychedelic therapy in depression and substance use disorders

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Reviewing the Potential of Psychedelics for the Treatment of PTSD

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Morphological cues to verb meaning: verb inflections and the initial mapping of verb meanings

Exploring the regulatory framework of psychedelics in the US & Europe

Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics